-
Evercore Analyzed 16 Years Of Biotech IPO Data
Monday, July 13, 2015 - 3:50pm | 485Biotech IPOs have long been alluring for investors because of how difficult it is to resist buying into the opportunity for a major biotech breakthrough. Shareholders of the company that finally cures cancer will likely all be instant millionaires, so why not take a stake in the next hot biotech...